Literature DB >> 17595541

Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.

Inga Odenholt1, Mats Walder, Marlene Wullt.   

Abstract

BACKGROUND: Pharmacodynamic studies of antibiotics have attracted great interest in recent years. However, studies on the pharmacodynamics of different antibiotics against Clostridium difficile are scarce.
METHODS: The postantibiotic effects (PAE) and the postantibiotic sub-minimum inhibitory concentration (MIC) effects (PA SME) of vancomycin, metronidazole and fusidic acid were investigated by viable counts against three different strains of C. difficile. The killing rate and extent of the three antibiotics against the same strains were also studied by adding 2, 4, 8, 16 and 32x MIC of the three antibiotics, respectively.
RESULTS: Metronidazole exerted a very rapid bactericidal effect at concentrations of 8x MIC and above against all three strains investigated. Vancomycin gave overall less kill in comparison to metronidazole and was bacteriostatic against two of the three strains. Fusidic acid exerted a concentration-dependent killing against two of the strains. Vancomycin exerted short PAEs and PA SMEs against all three strains. Significantly longer PAEs and PA SMEs were noted for fusidic acid. Metronidazole gave similar short PAEs like vancomycin but longer PA SMEs were noted against two of the investigated strains.
CONCLUSION: Metronidazole exerted the most prominent bactericidal effect greater than fusidic acid and greater than vancomycin. Fusidic acid gave overall the longest PAEs and PA SMEs greater than metronidazole and greater than vancomycin. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595541     DOI: 10.1159/000104471

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

Review 1.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

2.  Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Authors:  Farah Babakhani; Abraham Gomez; Nikki Robert; Pamela Sears
Journal:  J Med Microbiol       Date:  2011-02-24       Impact factor: 2.472

3.  Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Authors:  Farah Babakhani; Abraham Gomez; Nikki Robert; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

4.  Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.

Authors:  Nader S Abutaleb; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  New antimicrobial agents for patients with Clostridium difficile infections.

Authors:  John G Bartlett
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

6.  In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.

Authors:  D Corbett; A Wise; S Birchall; P Warn; S D Baines; G Crowther; J Freeman; C H Chilton; J Vernon; M H Wilcox; R J Vickers
Journal:  J Antimicrob Chemother       Date:  2015-02-03       Impact factor: 5.790

7.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

8.  Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay.

Authors:  Angie M Jarrad; Mark A T Blaskovich; Anggia Prasetyoputri; Tomislav Karoli; Karl A Hansford; Matthew A Cooper
Journal:  Front Microbiol       Date:  2018-07-02       Impact factor: 5.640

9.  Effect of sub-MIC values of metronidazole, ciprofloxacin, and imipenem on the growth and toxin production in Clostridioides difficile.

Authors:  Farahnaz Sadat Shayegan Mehr; Masoumeh Azimirad; Seyedeh Nazanin Mansouri Gilani; Ayub Ghafurian; Abbas Yadegar
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

Review 10.  A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.

Authors:  Xiuzhen Di; Nan Bai; Xin Zhang; Bin Liu; Wentao Ni; Jin Wang; Kai Wang; Beibei Liang; Youning Liu; Rui Wang
Journal:  Braz J Infect Dis       Date:  2015-05-19       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.